TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17006117
Drug: Benzydamine 0.15%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzydamine 0.15% wt/vol oral rinse
Study: 14602795
Drug: Recombinant GH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant GH (5 micro g/kg.d)
Study: 14602795
Drug: GH receptor
Normalized name: Toll-like receptor 9
DrugBank: Toll-like receptor 9 (DB15320)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH receptor antagonism
Study: 2946507
Drug: Isradipine 10
Normalized name: isradipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine 10 mg b.i.d.
Study: 2946507
Drug: Isradipine 20
Normalized name: Isradipine
DrugBank: Isradipine (DB00270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isradipine 20 mg b.i.d.
Study: 20230914
Drug: Soy isoflavones
Normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy isoflavones 200mg daily
Study: 12878791
Drug: Recent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recent treatment protocol (surgery, craniospinal irradiation, 4 courses of chemotherapy including VCR, VP, CBDCA, CTX, IF, CDDP, followed by 8 courses of maintenance chemotherapy with VCR, CDDP, CCNU)
Study: 12878791
Drug: Earlier treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Earlier treatment protocol (surgery and radiotherapy followed by chemotherapy)
Study: 12878791
Drug: Recent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recent treatment protocol for high-risk patients
Study: 12878791
Drug: Earlier treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Earlier treatment protocol for high-risk patients
Study: 7875183
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg ibopamine (IBO)
Study: 7875183
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg isosorbide mononitrate (ISMN)
Study: 2831248
Drug: Test diet
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test diet (1660 mg phosphorus, 420 mg calcium)
Study: 2831248
Drug: Control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diet (820 mg calcium, 930 mg phosphorus)
Study: 19593941
Drug: 1 gram
Normalized name: guar gum 1 gram ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 gram of fish oil daily for 6 months (containing 180 mg eicosapentaenoic acid and 120 mg docosahexaenoic acid)
Study: 15136062
Drug: L-arginine (6g
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (6g per day)
Study: 10193230
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch with infiltration analgesia (2 ml lignocaine 2% with adrenaline)
Study: 26317258
Drug: Continuous local
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous local wound infusion treatment in addition to WHO standard pain management protocol (Group 1)
Study: 26317258
Drug: Continuous local
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous local wound infusion treatment (Group 1)
Study: 21398011
Drug: 0.05% tranexamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% tranexamic acid in normal saline solution
Study: 10756406
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CC)
Study: 7343379
Drug: Metoprolol RETARD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol RETARD 100 mg
Study: 7343379
Drug: Metoprolol RETARD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol RETARD 200 mg
Study: 29892933
Drug: TJ-100 (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: TJ-100 (15 g/day)
Study: 22102633
Drug: 40 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/kg allopurinol (with an interval of 12 h) starting within 4 h after birth
Study: 20429491
Drug: Antibiotics treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics treatment for trichomoniasis (365 women, 83%)
Study: 20429491
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment for trichomoniasis (63 women, 15%)
Study: 17047001
Drug: TEC (docetaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: TEC (docetaxel 75 mg/m2, epirubicin 75 mg/m2, cyclophosphamide 500 mg/m2) every 3 weeks
Study: 17047001
Drug: EC‐‐>T (E
Approvals — FDA: no, EMA: no, PMDA: no
Description: EC‐‐>T (E 100 mg/m2, C 600 mg/m2 x 4, then T 100 mg/m2 x 4) every 2 weeks
Study: 17047001
Drug: T‐‐>EC (T
Approvals — FDA: no, EMA: no, PMDA: no
Description: T‐‐>EC (T 100 mg/m2 x 4, then E 100 mg/m2, C 600 mg/m2 x 4) every 2 weeks
Study: 2227588
Drug: Cisplatin 100
Normalized name: CISPLATIN 100MG/VIL (PF) INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 100 mg/m2 every 28 days
Study: 2227588
Drug: Carboplatin 400
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin 400 mg/m2 every 28 days
Study: 2227588
Drug: Cisplatin second-line
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin second-line treatment
Study: 2227588
Drug: Carboplatin second-line
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin second-line treatment
Study: 24170763
Drug: Premixed insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Premixed insulin lispro (insulin lispro mix 25 and/or insulin lispro mix 50)
Study: 24170763
Drug: Basal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal insulin glargine plus up to three injections of insulin lispro
Study: 12913774
Drug: Dexamethasone (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.6 mg/kg/day in four doses for 48 h)
Study: 8536777
Drug: DMPA 150
Normalized name: DMPA
DrugBank: Zytron (DB11768)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMPA 150 mg single-dose intramuscular injection
Study: 1780418
Drug: 2DG (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2DG (50 mg/kg)
Study: 24149401
Drug: Oral tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tranexamic acid (TA) - 1 g starting 2 hours before surgery, 3 g daily in divided doses (1 g every 8 hours) for 5 days
Study: 24149401
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone - single dose of 1 mg/kg at the beginning of surgery
Study: 24343761
Drug: E2212 (10-250
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2212 (10-250 mg, single ascending oral doses)
Study: 24343761
Drug: E2212 (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2212 (250 mg cohort)
Study: 19237833
Drug: H(2) receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: H(2) receptor antagonists (H(2)RA)
Study: 15203796
Drug: Venlafaxine (antidepressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine (antidepressant medication) plus standard care (brief counseling and nicotine replacement therapy)
Study: 15203796
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus standard care (brief counseling and nicotine replacement therapy)
Study: 8040679
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate (HD-MTX) treatment (900 to 3,700 mg/m2 intravenously over 24 hours)
Study: 2923290
Drug: Caudal injection
Normalized name: LIDOCAINE HYDROCHLORIDE 10 mg in 1 mL INTRACAUDAL INJECTION, SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal injection of preservative-free morphine sulfate (0.075 mg/kg) in preservative-free normal saline (5-10 ml)
Study: 4914612
Drug: Phenformin 100mg
Normalized name: phenformin
DrugBank: Phenformin (DB00914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenformin 100mg daily for six weeks
Study: 4914612
Drug: Inert capsules
Normalized name: inert ingredients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inert capsules for six weeks
Study: 28662983
Drug: Adipose tissue-derived
Normalized name: human adipose preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adipose tissue-derived mesenchymal stromal cells (AT-MSCs) at a dosage of 1×10^6/kg (group A, n=9) or 3×10^6/kg (group B, n=5) with cyclosporine and prednisone as first-line therapy
Study: 23261916
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy group
Study: 10475716
Drug: Buspirone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (5 mg, p.o.)
Study: 10475716
Drug: Diazepam (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (2 mg, p.o.)
Study: 10475716
Drug: Fluvoxamine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (25 mg, p.o.)
Study: 1387866
Drug: Vaccine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine plus HBIG
Study: 6149939
Drug: bisoprolol 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: bisoprolol 20 mg
Study: 6149939
Drug: terbutaline up
Approvals — FDA: no, EMA: no, PMDA: no
Description: terbutaline up to 3.5 mg
Study: 30424482
Drug: New Zealand
Normalized name: NEW ZEALAND GREEN MUSSEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: New Zealand blackcurrant extract (NZBC) - 600 mg total (two capsules of 300 mg each containing 35% blackcurrant extract)
Study: 25233157
Drug: Reamed nail
Normalized name: FUNGI NAIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reamed nail treatment
Study: 22714001
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg daclatasvir
Study: 22714001
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg daclatasvir
Study: 22714001
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg daclatasvir
Study: 17312304
Drug: Tamoxifen (during
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (during active treatment)
Study: 17312304
Drug: Tamoxifen (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (after treatment)
Study: 12716266
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (Fluoxetine or Nortriptyline)
Study: 27110603
Drug: Apically positioned
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apically positioned flap with buccal approach (APF-B)
Study: 27110603
Drug: Apically positioned
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apically positioned flap with buccal and palatal approach (APF-BP)
Study: 21031576
Drug: Transdermal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal therapy with a mixture of 3 myelin peptides: MBP85-99, PLP139-151, and MOG35-55
Study: 19007923
Drug: Cognitive behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behaviour therapy (CBT) for BN
Study: 15994746
Drug: Fixed-dose GH
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose GH treatment
Study: 8699994
Drug: Intravenous ATP
Normalized name: ATP
DrugBank: ATP (DB00171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ATP at 50 micrograms/kg/minute
Study: 8699994
Drug: Intravenous ATP
Normalized name: ATP
DrugBank: ATP (DB00171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ATP at 75 micrograms/kg/minute
Study: 8699994
Drug: Intravenous ATP
Normalized name: ATP
DrugBank: ATP (DB00171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ATP at 100 micrograms/kg/minute
Study: 8699994
Drug: Intravenous ATP
Normalized name: ATP
DrugBank: ATP (DB00171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ATP (all doses)
Study: 1928853
Drug: T3 and
Normalized name: T3
DrugBank: Liothyronine (DB00279)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: T3 and hydrocortisone (100 mg hydrocortisone intravenously, 2 or 4 micrograms T3 every hour or half hour)
Study: 30743314
Drug: Voxelotor 900
Normalized name: Voxelotor
DrugBank: Voxelotor (DB14975)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Voxelotor 900 mg for 15 days
Study: 30743314
Drug: Voxelotor (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voxelotor (various doses: 100, 400, 1000, 2000, or 2800 mg) single dose
Study: 30743314
Drug: Voxelotor (300,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voxelotor (300, 600, or 900 mg) multiple doses for 15 days
Study: 30743314
Drug: Voxelotor in
Normalized name: Product containing voxelotor in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voxelotor in SCD patients (1000 mg)
Study: 30743314
Drug: Voxelotor (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voxelotor (various doses)
Study: 11748776
Drug: Citalopram augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram augmentation (20-40 mg/day)
Study: 11748776
Drug: No citalopram
Approvals — FDA: no, EMA: no, PMDA: no
Description: No citalopram augmentation
Study: 3717618
Drug: Lidocaine with
Normalized name: Lidocaine with Tegaderm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine with 2 mg phenylephrine
Study: 3717618
Drug: Lidocaine with
Normalized name: Lidocaine with Tegaderm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine with 5 mg phenylephrine
Study: 27905884
Drug: Pivmecillinam 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pivmecillinam 400 mg t.i.d. for 3 days
Study: 27905884
Drug: Pivmecillinam 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pivmecillinam 400 mg b.i.d. for 5 days
Study: 25286026
Drug: Placebo (twice-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (twice-daily placebo)
Study: 19001772
Drug: 4 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g/d XOS for 8 weeks
Study: 12091259
Drug: Active nutritional
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active nutritional supplements (vitamins, minerals, essential fatty acids)
Study: 9527094
Drug: Atrial natriuretic
Normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial natriuretic peptide infusion
Study: 7867113
Drug: Group C‐‐subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C‐‐subcutaneous ring block
Study: 7867113
Drug: Group D‐‐a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group D‐‐a combination of frenulum infiltration and the '10, 30‐13, 30' approach
Study: 7867113
Drug: Group E‐‐a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group E‐‐a combination of frenulum infiltration and the subpubic approach
Study: 7867113
Drug: Subcutaneous ring
Normalized name: RING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous ring block or a combination of dorsal nerve block (using the '10, 30‐13, 30' or the subpubic approach) and infiltration of the frenulum
Study: 2671200
Drug: Vinburnin (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinburnin (45 mg iv per day)
Study: 991148
Drug: Cytosine arabinoside
Normalized name: Cytosine arabinoside
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cytosine arabinoside (CA) synchronization plus vincristine, prednisone, and L-asparaginase
Study: 23106186
Drug: Dexmedetomidine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.5 μg.kg(‐1)
Study: 23106186
Drug: Dexmedetomidine 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 1.0 μg.kg(‐1)
Study: 19361897
Drug: Sodium intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium intake <3 g/day (group 1)
Study: 19361897
Drug: Sodium intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium intake >6 g/day (group 2)
Study: 15275792
Drug: Neurolytic sympathetic
Normalized name: Bos taurus sympathetic nerve preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurolytic sympathetic plexus block (NSPB) with alcohol in patients using NSAID and a weak oral opioid or morphine (dose ≤90 mg/day)
Study: 15275792
Drug: Neurolytic sympathetic
Normalized name: Bos taurus sympathetic nerve preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurolytic sympathetic plexus block (NSPB) with alcohol in patients using NSAID and morphine (dose ≥90 mg/day)
Study: 15275792
Drug: Pharmacological therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological therapy only (Control group)
Study: 9070471
Drug: Ibuprofen (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (10 mg per kilogram of body weight, max 800 mg, given every six hours for eight doses)
Study: 8363997
Drug: tropisetron (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: tropisetron (5 mg i.v. Day 1; 5 mg p.o. Days 2-6)
Study: 31844890
Drug: VB-111 1013
Normalized name: VB-201
DrugBank: VB-201 (DB15259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VB-111 1013 viral particles every 8 weeks in combination with bevacizumab 10 mg/kg every 2 weeks
Study: 31844890
Drug: VB-111 and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: VB-111 and bevacizumab combination
Study: 28258773
Drug: Celecoxib 400
Normalized name: celecoxib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 400 mg administered 1 hour before surgery
Study: 19842230
Drug: Concurrent neoadjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent neoadjuvant chemoradiotherapy
Study: 19842230
Drug: Sequential neoadjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential neoadjuvant chemoradiotherapy
Study: 7923516
Drug: Atracurium 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium 0.75 mg.kg‐1
Study: 7923516
Drug: Atracurium 1
Normalized name: cisatracurium 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium 1 mg.kg‐1
Study: 7923516
Drug: Succinylcholine 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylcholine 1.5 mg.kg‐1 (Control)
Study: 3407900
Drug: Oral intubation
Normalized name: ADAPTER,INTUBATION CAREFUSION #1820
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral intubation with a laryngoscope (Group A, n = 50)
Study: 18251642
Drug: Ultrasound therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound therapy delivered for 20 minutes using a piezoelectric transducer for 10 sessions over 4 weeks.
Study: 18251642
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no ultrasound therapy)
Study: 17034311
Drug: Salbutamol 200
Normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol 200 microg (metered dose inhaler)
Study: 14605789
Drug: Microcrystalline chitosan
Normalized name: Chitosan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microcrystalline chitosan (MCC) 1.2 g twice daily
Study: 14605789
Drug: Placebo 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1.2 g twice daily
Study: 9232667
Drug: Dextromethorphan (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextromethorphan (30 mg single dose)
Study: 2982694
Drug: Vegetable protein
Normalized name: Hydrogenated Vegetable Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vegetable protein diet supplemented with psyllium fiber (0.8 g/kg body wt, 1800 kcal/day)
Study: 2982694
Drug: Meat protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meat protein diet (0.8 g/kg body wt, approximately 1800 kcal/day) plus neomycin and laxatives
Study: 27613912
Drug: Combined nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined nicotine replacement therapy (NRT) and behavioral counseling
Study: 25033113
Drug: Group-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-based cognitive processing therapy (CPT)
Study: 17969818
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin treatment (short‐acting insulin in each meal and medium‐acting insulin before going to bed)
Study: 17969818
Drug: Conventional insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional insulin treatment (two doses: morning and evening)
Study: 8272992
Drug: Bupivacaine 0.5%
Normalized name: BUPivacaine 0.5% injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.5% (8 ml) infiltrated 5 min before incision
Study: 2888424
Drug: Cetirizine 2
Normalized name: cetirizine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine 2 HCl 10 mg
Study: 27899130
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment (cephalexin)
Study: 20845288
Drug: Intranasal desmopressin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal desmopressin 40 µg
Study: 20845288
Drug: Intranasal desmopressin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal desmopressin 40 µg plus intramuscular tramadol 100 mg
Study: 12648180
Drug: 150 micro
Normalized name: Norgestrel 150 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 micro g Nestorone
Study: 12648180
Drug: 200 micro
Normalized name: Digoxin 200 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 micro g Nestorone
Study: 12648180
Drug: 400 micro
Normalized name: EM 2400 Micro Volume
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 micro g Nestorone
Study: 11063500
Drug: Clarithromycin 500
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 500 mg twice a day from the day before to 3 days after mastectomy
Study: 8931784
Drug: Thalidomide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide (100 mg by mouth, four times daily) for 12 weeks
Study: 30852478
Drug: Alteplase intravenous
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alteplase intravenous thrombolysis
Study: 29378038
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g cashew nuts/day for 12 weeks
Study: 22668876
Drug: PEG‐IFN α‐2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐IFN α‐2a (180 μg weekly) ± ribavirin (1000‐1200 mg daily) for 48 weeks
Study: 17506733
Drug: Midazolam-propofol group
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Midazolam-propofol group (midazolam at 0.1 mg.kg(‐1) followed by propofol at 1.5 mg.kg(‐1))
Study: 17506733
Drug: Propofol group
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol group (propofol at 2.5 mg.kg(‐1))
Study: 16163516
Drug: MDMA (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA (2 mg/kg, p.o.)